Dominik Schum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dominik Schum has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Stephan Axel Sieber
Center for Functional Protein Assemblies (CPA) Department of Bioscience, TUM School of Natural Sciences Technical University of Munich (TUM) Garching Germany
4 shared publications - Joshua Hesse
Technical University of Munich
2 shared publications - Annkathrin I. Bohne
Technical University of Munich
1 shared publication Daisuke Sasaki
Department of Surgery, Klinikum rechts der Isar, School of Medicine and Health, Technical University of Munich, Munich, Germany
1 shared publicationDietmar H. Pieper
Helmholtz Centre for Infection Research, Microbial Interactions and Processes, Inhoffenstraße 7, 38124 Braunschweig, Germany
1 shared publication- Dominik P. Halter
Technical University of Munich
1 shared publication
Latest Publications
- Open Access
Decoding antibiotic modes of action from multimodal cellular responses
Antibiotic resistance continues to rise, yet most new drug candidates act through long-established targets. Faster mode of action (MoA) assessment would enable more effective prioritization of screening hits and help identify compounds with novel mechanisms. In this study, we aimed to develop a scalable framework for MoA inference from antibiotic-induced cellular response profiles in Escherichia coli . We generated a multimodal dataset spanning more than 50 antibiotics, including proteome profiles, chemical structure descriptors, inhibitory concentrations and growth dynamics, and used it to build MAPPER (Mode of Action Prediction via Proteomics-Enhanced Representation), a framework comprising a fixed multimodal predictor and an uncertainty module. MAPPER accurately classified antibiotics across nine mechanistic classes, flagged compounds with likely novel mechanisms and retained predictive power in proteomics-only transfer experiments across mass spectrometry platforms and external data. Together, these results establish MAPPER as an innovative tool for MoA prediction and novelty detection, enabling prioritization of antibacterial candidates with distinct mechanisms.
Open AccessDecoding antibiotic modes of action from multimodal cellular responses
Antibiotic resistance continues to rise, yet most new drug candidates act through long-established targets. Faster mode of action (MoA) assessment would enable more effective prioritization of screening hits and help identify compounds with novel mechanisms. In this study, we aimed to develop a scalable framework for MoA inference from antibiotic-induced cellular response profiles in Escherichia coli . We generated a multimodal dataset spanning more than 50 antibiotics, including proteome profiles, chemical structure descriptors, inhibitory concentrations and growth dynamics, and used it to build MAPPER (Mode of Action Prediction via Proteomics-Enhanced Representation), a framework comprising a fixed multimodal predictor and an uncertainty module. MAPPER accurately classified antibiotics across nine mechanistic classes, flagged compounds with likely novel mechanisms and retained predictive power in proteomics-only transfer experiments across mass spectrometry platforms and external data. Together, these results establish MAPPER as an innovative tool for MoA prediction and novelty detection, enabling prioritization of antibacterial candidates with distinct mechanisms.
- Open Access
- 9 September 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (9) , 4249-4259
Generative Deep Learning Pipeline Yields Potent Gram-Negative Antibiotics
The escalating crisis of multiresistant bacteria demands the rapid discovery of novel antibiotics that transcend the limitations imposed by the biased chemical space of current libraries. To address this challenge, we introduce an innovative deep learning-driven pipeline for de novo antibiotic design. Our unique approach leverages a chemical language model to generate structurally unprecedented antibiotic candidates. The model was trained on a diverse chemical space of drug-like molecules and natural products. We then applied transfer learning using a data set of diverse antibiotic scaffolds to refine its generative capabilities. Using predictive modeling and expert curation, we prioritized the most promising compounds for synthesis. This pipeline identified a lead candidate with potent activity against methicillin-resistant Staphylococcus aureus. We then performed iterative refinement by synthesizing 40 derivatives of the lead compound. This effort produced a suite of active compounds, with 30 showing activity against S. aureus and 17 against Escherichia coli. Among these, lead compound D8 exhibited remarkable submicromolar and single-digit micromolar potency against the aforementioned pathogens, respectively. Mechanistic investigations point to the reductive generation of reactive species as its primary mode of action. This work validates a deep-learning pipeline that explores chemical space to generate antibiotic candidates. This process yields a potent nitrofuran derivative and a set of experimentally validated scaffolds to seed future antibiotic development.
- 9 September 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (9) , 4249-4259
Open AccessGenerative Deep Learning Pipeline Yields Potent Gram-Negative Antibiotics
The escalating crisis of multiresistant bacteria demands the rapid discovery of novel antibiotics that transcend the limitations imposed by the biased chemical space of current libraries. To address this challenge, we introduce an innovative deep learning-driven pipeline for de novo antibiotic design. Our unique approach leverages a chemical language model to generate structurally unprecedented antibiotic candidates. The model was trained on a diverse chemical space of drug-like molecules and natural products. We then applied transfer learning using a data set of diverse antibiotic scaffolds to refine its generative capabilities. Using predictive modeling and expert curation, we prioritized the most promising compounds for synthesis. This pipeline identified a lead candidate with potent activity against methicillin-resistant Staphylococcus aureus. We then performed iterative refinement by synthesizing 40 derivatives of the lead compound. This effort produced a suite of active compounds, with 30 showing activity against S. aureus and 17 against Escherichia coli. Among these, lead compound D8 exhibited remarkable submicromolar and single-digit micromolar potency against the aforementioned pathogens, respectively. Mechanistic investigations point to the reductive generation of reactive species as its primary mode of action. This work validates a deep-learning pipeline that explores chemical space to generate antibiotic candidates. This process yields a potent nitrofuran derivative and a set of experimentally validated scaffolds to seed future antibiotic development.
- Open Access
- 16 July 2024
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 4 (8) , 3125-3134
Screening Privileged Alkyl Guanidinium Motifs under Host-Mimicking Conditions Reveals a Novel Antibiotic with an Unconventional Mode of Action
Screening large molecule libraries against pathogenic bacteria is often challenged by a low hit rate due to limited uptake, underrepresentation of antibiotic structural motifs, and assays that do not resemble the infection conditions. To address these limitations, we present a screen of a focused library of alkyl guanidinium compounds, a structural motif associated with antibiotic activity and enhanced uptake, under host-mimicking infection conditions against a panel of disease-associated bacteria. Several hit molecules were identified with activities against Gram-positive and Gram-negative bacteria, highlighting the fidelity of the general concept. We selected one compound (L15) for in-depth mode of action studies that exhibited bactericidal activity against methicillin-resistant Staphylococcus aureus USA300 with a minimum inhibitory concentration of 1.5 μM. Structure-activity relationship studies confirmed the necessity of the guanidinium motif for antibiotic activity. The mode of action was investigated using affinity-based protein profiling with an L15 probe and identified the signal peptidase IB (SpsB) as the most promising hit. Validation by activity assays, binding site identification, docking, and molecular dynamics simulations demonstrated SpsB activation by L15, a recently described mechanism leading to the dysregulation of protein secretion and cell death. Overall, this study highlights the need for unconventional screening strategies to identify novel antibiotics.
- 16 July 2024
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 4 (8) , 3125-3134
Open AccessScreening Privileged Alkyl Guanidinium Motifs under Host-Mimicking Conditions Reveals a Novel Antibiotic with an Unconventional Mode of Action
Screening large molecule libraries against pathogenic bacteria is often challenged by a low hit rate due to limited uptake, underrepresentation of antibiotic structural motifs, and assays that do not resemble the infection conditions. To address these limitations, we present a screen of a focused library of alkyl guanidinium compounds, a structural motif associated with antibiotic activity and enhanced uptake, under host-mimicking infection conditions against a panel of disease-associated bacteria. Several hit molecules were identified with activities against Gram-positive and Gram-negative bacteria, highlighting the fidelity of the general concept. We selected one compound (L15) for in-depth mode of action studies that exhibited bactericidal activity against methicillin-resistant Staphylococcus aureus USA300 with a minimum inhibitory concentration of 1.5 μM. Structure-activity relationship studies confirmed the necessity of the guanidinium motif for antibiotic activity. The mode of action was investigated using affinity-based protein profiling with an L15 probe and identified the signal peptidase IB (SpsB) as the most promising hit. Validation by activity assays, binding site identification, docking, and molecular dynamics simulations demonstrated SpsB activation by L15, a recently described mechanism leading to the dysregulation of protein secretion and cell death. Overall, this study highlights the need for unconventional screening strategies to identify novel antibiotics.
- Open Access
- 28 May 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-11
Bacillamide D produced by Bacillus cereus from the mouse intestinal bacterial collection (miBC) is a potent cytotoxin in vitro
The gut microbiota influences human health and the development of chronic diseases. However, our understanding of potentially protective or harmful microbe-host interactions at the molecular level is still in its infancy. To gain further insights into the hidden gut metabolome and its impact, we identified a cryptic non-ribosomal peptide BGC in the genome of Bacillus cereus DSM 28590 from the mouse intestine (www.dsmz.de/miBC), which was predicted to encode a thiazol(in)e substructure. Cloning and heterologous expression of this BGC revealed that it produces bacillamide D. In-depth functional evaluation showed potent cytotoxicity and inhibition of cell migration using the human cell lines HCT116 and HEK293, which was validated using primary mouse organoids. This work establishes the bacillamides as selective cytotoxins from a bacterial gut isolate that affect mammalian cells. Our targeted structure-function-predictive approach is demonstrated to be a streamlined method to discover deleterious gut microbial metabolites with potential effects on human health.
- 28 May 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-11
Open AccessBacillamide D produced by Bacillus cereus from the mouse intestinal bacterial collection (miBC) is a potent cytotoxin in vitro
The gut microbiota influences human health and the development of chronic diseases. However, our understanding of potentially protective or harmful microbe-host interactions at the molecular level is still in its infancy. To gain further insights into the hidden gut metabolome and its impact, we identified a cryptic non-ribosomal peptide BGC in the genome of Bacillus cereus DSM 28590 from the mouse intestine (www.dsmz.de/miBC), which was predicted to encode a thiazol(in)e substructure. Cloning and heterologous expression of this BGC revealed that it produces bacillamide D. In-depth functional evaluation showed potent cytotoxicity and inhibition of cell migration using the human cell lines HCT116 and HEK293, which was validated using primary mouse organoids. This work establishes the bacillamides as selective cytotoxins from a bacterial gut isolate that affect mammalian cells. Our targeted structure-function-predictive approach is demonstrated to be a streamlined method to discover deleterious gut microbial metabolites with potential effects on human health.